AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02938559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) for depression + Memory Support
Description: The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
Study NCT00723723 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: Statin
Study NCT04111055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Description: the CLV system will correct hypotension by automated adjustment of norepinephrine.
Study NCT02801396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A (Control)
Study NCT02740881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counselor Training Methods
Study NCT02646852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX038
Study NCT02740881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselor Training Methods
Study NCT02083783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRI102
Description: formulation containing active moiety (amphetamine)
Study NCT02083783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: formulation without active moiety
Study NCT02675439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADU-S100
Study NCT06508398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological Diagnostic Testing
Description: This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:~Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.~Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.~Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.~Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.~This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs.
Study NCT04080375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Description: the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
Study NCT04080375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the patient will take one vaginal tablet of placebo 1 hour before surgery
Study NCT03958851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasonography of renal arteries
Description: Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :~RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken.
Study NCT03958851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Renal biopsy
Description: Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
Study NCT03958851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function tests
Description: blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
Study NCT03958851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The 24-hour urine protein test
Description: The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
Study NCT03958851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: complete blood counting (CBC)
Description: A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
Study NCT01375244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Tablets, 10 mg, single dose
Study NCT01375244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestril
Description: Tablets, 10 mg, single dose
Study NCT03962842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates method
Description: The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
Study NCT04486105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: pure sucrose in water in addition to habitual diet
Study NCT01279967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: 36.8mg/m2 based on BSA, weekly treatment for 6 months
Study NCT02675439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Study NCT04226326 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Directly measure microvascular function using direct coronary flow measurements
Description: The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
Study NCT01339780 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BS, SPECT/CT, PET/CT, MRI
Description: Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
Study NCT04486105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: pure sucrose in water in addition to habitual diet
Study NCT02094677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon II 3
Description: Participants were randomized to wear filcon II 3 test lens.
Study NCT02094677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Participants were randomized to wear etafilcon A control lens.
Study NCT02094677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: Participants were randomized to wear nelfilcon A control lens.
Study NCT00390468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandutinib
Description: 500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
Study NCT01871415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily
Study NCT00545662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
Study NCT00545662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citicoline
Description: 1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
Study NCT02923960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ONS
Description: One serving (237 ml) standard oral nutritional beverage
Study NCT02923960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes specific ONS 1
Description: One serving (237 ml) diabetes oral nutritional beverage
Study NCT02923960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes specific ONS 2
Description: One serving (296 ml) diabetes oral nutritional beverage
Study NCT03873831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The therapy dog is present during the session.
Study NCT03873831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social skills group
Description: The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists.
Study NCT03873831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills group
Description: The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists.
Study NCT02756013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
Study NCT02756013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
Study NCT04185428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Therapy
Description: still meditation, meditative movement, relaxation techniques, and massage therapy
Study NCT03131765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS-0N-001
Description: Cancer vaccine
Study NCT00727493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate once weekly 70mg
Description: alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
Study NCT00727493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
Study NCT01871415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: pre-existing background regimen and dose
Study NCT04227847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD70
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
Study NCT04227847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: 75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
Study NCT03207867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.~NIR178 was administered orally twice daily (BID) as a capsule (Part 1, Part 2 and Japanese safety run-in) and as a film-coated table (Part 3). There were up to 3 dose levels assessed: 80, 160 and 240 mg. Three alternative dosing schedules were evaluated: continuous (Part 1, Part 2, Part 3, Japanese safety run-in), 2 weeks on/2 weeks off (Part 2) and 1 week on/1 week off (Part 2).~Each cycle consisted of 28 days.
Study NCT03207867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a human monoclonal antibody (MAb) administered on Day 1 of each cycle. PDR001 400 mg was administered via intravenous (i.v.) infusion over 30 minutes every 4 weeks (Q4W).
Study NCT01169428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Weight Loss Maintenance (MBWLM)
Description: This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
Study NCT01169428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Standard Behavioral Weight-Loss Maintenence
Description: Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors \[e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information \& education\]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
Study NCT05527574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
Study NCT00829803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SNAP monitor; Bispectral Index Monitor (BIS Monitor)
Description: Intended to monitor the state of the brain by data acquisition of EEG signals.
Study NCT00829803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNAP monitor; Bispectral Index Monitor (BIS Monitor)
Description: Intended to monitor the state of the brain by data acquisition of EEG signals.
Study NCT00996775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief alcohol intervention
Description: this intervention consists of brief assessment and feedback
Study NCT00996775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: education about harmful effects of alcohol use and NIAAA recommended drinking limits
Study NCT00110136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort
Description: St. John's Wort 300mg tablet three times per day
Study NCT00684346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18-FDG
Description: The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
Study NCT02139631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
Study NCT00848471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quark RMR
Description: Quark RMR calorimeter (Cosmed)
Study NCT00848471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deltatrac II
Description: Deltatrac II (GE health Care Clinical Systems)
Study NCT02250378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT02250378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo wedge resection
Study NCT02250378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02250378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02644135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halo Oral Spray
Description: Three sprays per use, total = 9 sprays per day
Study NCT02644135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Halo Placebo
Description: Three sprays per use, total = 9 sprays per day
Study NCT06478485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No Intervention: MCSM
Description: No Intervention: MCSM
Study NCT01516346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
Study NCT01516346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate + Hydralazine
Description: Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
Study NCT01516346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
Study NCT00952575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyclonal anti-D immunoglobulin
Description: single injection of 300 µg
Study NCT00952575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monoclonal anti-D immunoglobulin
Description: Comparison of different dosages of LFB-R593
Study NCT03673215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
Study NCT03673215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
Study NCT03673215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.